Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

206,007 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation.
Zhang T, Pan Z, Gao J, Wu Q, Bai G, Li Y, Tong L, Feng F, Lai M, Liu Y, Song P, Ning Y, Tang H, Luo W, Chen Y, Fang Y, Zhang H, Liu Q, Zhang Y, Wang H, Chen Z, Chen Y, Geng M, Ji H, Zhao G, Zhou H, Ding J, Xie H. Zhang T, et al. Among authors: liu y, liu q. Signal Transduct Target Ther. 2024 Aug 15;9(1):216. doi: 10.1038/s41392-024-01928-8. Signal Transduct Target Ther. 2024. PMID: 39143065 Free PMC article.
Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
Liu YQ, Wang YN, Lu XY, Tong LJ, Li Y, Zhang T, Xun QJ, Feng F, Chen YZ, Su Y, Shen YY, Chen Y, Geng MY, Ding K, Li YL, Xie H, Ding J. Liu YQ, et al. Acta Pharmacol Sin. 2018 Nov;39(11):1768-1776. doi: 10.1038/s41401-018-0056-0. Epub 2018 Jul 3. Acta Pharmacol Sin. 2018. PMID: 29968849 Free PMC article.
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, Chen H, Song T, Song P, Bai G, Liu Y, Wang Y, Li Y, Su Y, Shen Y, Sun Y, Chen Y, Geng M, Ding K, Ding J, Xie H. Zhang T, et al. Among authors: liu y. Mol Cancer. 2021 Aug 17;20(1):102. doi: 10.1186/s12943-021-01391-x. Mol Cancer. 2021. PMID: 34404402 Free PMC article. No abstract available.
Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T, Qu R, Chan S, Lai M, Tong L, Feng F, Chen H, Song T, Song P, Bai G, Liu Y, Wang Y, Li Y, Su Y, Shen Y, Sun Y, Chen Y, Geng M, Ding K, Ding J, Xie H. Zhang T, et al. Among authors: liu y. Mol Cancer. 2023 Aug 19;22(1):139. doi: 10.1186/s12943-023-01842-7. Mol Cancer. 2023. PMID: 37598189 Free PMC article. No abstract available.
A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy.
Liu Y, Tong L, Zhang M, Zhang Q, Liu Q, Feng F, Li Y, Lai M, Tang H, Chen Y, Geng M, Duan W, Ding J, Xie H. Liu Y, et al. Among authors: liu q. Cancer Commun (Lond). 2024 Mar;44(3):438-442. doi: 10.1002/cac2.12521. Epub 2024 Feb 9. Cancer Commun (Lond). 2024. PMID: 38335159 Free PMC article. No abstract available.
206,007 results
You have reached the last available page of results. Please see the User Guide for more information.